Company Overview of NanoCor Therapeutics, Inc.
NanoCor Therapeutics, Inc. develops therapeutics for the non-invasive treatment of various cardiovascular diseases at the molecular level. The company’s Carfostin is an intracellular protein therapeutic for the treatment of chronic heart failure. Its Carfostin comprises the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles and the self-complementary vector technology. The company was founded in 2005 and is based in Chapel Hill, North Carolina. NanoCor Therapeutics, Inc. is a former subsidiary of Asklepios BioPharmaceutical, Inc.
870 Martin Luther King Junior Boulevard
Chapel Hill, NC 27514
Founded in 2005
Key Executives for NanoCor Therapeutics, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact NanoCor Therapeutics, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.